Clinical trials: Renal Transplant Recipients
Kidney Diseases
Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no Steroids
Kidney transplant patients will be treated with Thymoglobulin (5 days), tacrolimus (Prograf), and mycophenolate mofetil (Cellcept) from the time of transplant.
- Trial name
- NCT00170053
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Mayo Clinic
type1diabetes, Renal Failure
Kidney Alone Versus Islet-After-Kidney in Type 1 Diabetic Kidney Transplant Recipient.
Islet transplantation is associated with a benefit on glycaemic control compared to optimized insulin therapy in recent clinical trials.
- Conditions
- type1diabetes, Renal Failure, End Stage Renal Disease
- Trial name
- KA-IAK (NCT05662267)
- Testing
- Pancreatic islet transplantation after kidney transplantation
- Where
- France
- Volunteers
- 327 people
- Sponsor
- University Hospital, Lille
Acute Kidney Injury, Chronic Kidney Diseases
Neohepatic Albumin-Bilirubin Scores on Renal Outcomes in Living-donor Liver Transplantation Recipients
This study investigates the association between post-reperfusion (neohepatic) ALBI scores and post-LT renal outcomes in living-donor LT (LDLT) recipients.
- Conditions
- Acute Kidney Injury, Chronic Kidney Diseases, Graft Failure
- Trial name
- NCT06340607
- Where
- South Korea
- Volunteers
- 3,422 people
- Sponsor
- Asan Medical Center
Kidney Transplantation
A Study to Assess the Safety and Efficacy of Prograf and MR4 in Kidney Transplantation Patients
To prove non-inferiority of MR4 to Prograf by evaluating the efficacy and safety of Prograf and MR4 in new kidney transplant recipients
- Trial name
- NCT00720265
- Testing
- Prograf, MR4
- Where
- 2 sites in South Korea
- Volunteers
- 135 people
- Sponsor
- Astellas Pharma Inc
Kidney Transplantation, Chronic Allograft Nephropathy
Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants
The purpose of this study is to see if kidney function can be improved during transplants by giving the drug Thymoglobulin with delayed cyclosporine treatment instead of initial cyclosporine treatment.
- Trial name
- NCT00007787
- Testing
- Cyclosporine, Anti-human thymocyte globulin (rabbit), Tacrolimus
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant Recipients
Role of Epoxyeicosatrienoic Acids in Chronic Allograft Nephropathy - The TRANSPLANT-EETs Study
Endothelial lesions within the transplanted kidney are a major determinant of chronic allograft nephropathy. Epoxyeicosatrienoic acids (EETs) are endothelium-derived hyperpolarizing factors with anti-inflammatory…
- Trial name
- TRANSPLANTEETs (NCT02555566)
- Testing
- Blood sampling, flow-mediated distal stimulation of the forearm radial artery by cutaneous heating
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Rouen
Immunocompromised Host, Organ Transplantation
Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease
Background: Solid organ transplantation provides life-saving treatment for end-stage organ disease but is associated with an increased cancer risk because of the need for long-term immunosuppression End-stage renal disease…
- Conditions
- Immunocompromised Host, Organ Transplantation, Cancer
- Trial name
- NCT00904579
- Where
- 9 sites in United States
- Volunteers
- 19,929,901 people
- Sponsor
- National Cancer Institute (NCI)
HBsAg(+) Donor Kidney Allograft, HBsAg(-) Donor Kidney Allograft
Hepatitis B Antigen Kidney Graft Into Protective Level Hepatitis B Antibody Recipients
To determine the safety of using kidney organ from hepatitis B surface antigen positive donor, the author conducted the single-center, prospective study of the use of these kidneys for recipients who have protective level of…
- Trial name
- NCT02044588
- Testing
- HBsAg positive kidney allograft donor
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- Chulalongkorn University
Kidney Transplantation, Chronic Kidney Disease
Calcineurin Free Immunosuppression in Renal Transplant Recipients
The main purpose of this study is to obtain preliminary information on the efficacy, safety and cost of two regimens, Rapamycin / MMF / steroid therapy and Cyclosporine A Neoral / MMF / steroid therapy, used in the prevention of…
- Trial name
- NCT00812123
- Testing
- Sirolimus, Cyclosporine A, Prednisone
- Where
- Switzerland
- Volunteers
- 127 people
- Sponsor
- University Hospital, Basel, Switzerland
End Stage Renal Disease, Hepatitis C
Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors
In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time.
- Trial name
- NCT04575896
- Testing
- Glecaprevir/pibrentasvir
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Kidney Transplantation
Study of Immunosuppressive Therapy Toxicities in Kidney Transplant Recipients at Regional or Satellite Community Clinics
This is a multicentre, observational, non-interventional, retrospective analysis by chart review.
- Trial name
- NCT00902980
- Testing
- Chart Review
- Where
- 13 sites in Canada
- Volunteers
- 264 people
- Sponsor
- Astellas Pharma Inc
Renal Transplant
Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients
Objective: Investigate the direct correlation of CYP3A5 genotype with tacrolimus trough levels and clinical outcomes. The primary endpoint of this study is to evaluate the proportion of patients reaching target levels (8-10…
- Trial name
- TAC3A5 (NCT03020589)
- Testing
- Tacrolimus
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- University of North Carolina, Chapel Hill
Renal Impairment, Liver Transplantation
CNI-free "Bottom"-up Immunosuppression in Patients Undergoing Liver Transplantation
The primary objective of the trial is to evaluate efficacy and safety of delayed introduction (up to 30 days post-transplantation in patients without signs of acute rejection that had received an aIL-2 induction and MMF) of…
- Conditions
- Renal Impairment, Liver Transplantation, Everolimus
- Trial name
- BUILT_01 (NCT01023542)
- Testing
- delayed, low-dose CNI, BU-CNI, BU-Everolimus
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- University of Regensburg
End Stage Renal Disease, Kidney Transplant; Complications
COVID Vaccine Immunity in Kidney Transplant Recipients
50 end-stage renal disease (ESRD) patients whom have had at least 2 doses of messenger ribonucleic acid (mRNA) vaccine, and undergoing transplantation at the University of Alabama at Birmingham (UAB) will be enrolled.
- Trial name
- NCT05387343
- Testing
- Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity Test
- Sponsor
- University of Alabama at Birmingham
Kidney Transplant Recipient, Heart Transplant Recipient
Pharmacokinetics of Mmf and Valganciclovir
The primary objective of this study is to determine whether a clinically significant PK drug interaction ( a 30% difference in the AUC of MPA) exists between mycophenolate mofetil (under steady state conditions) and VGCV in renal…
- Trial name
- NCT00189150
- Testing
- Mycophenolate mofetil, Valganciclovir
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan
Cytomegalovirus Infections
Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence
Cytomegalovirus is the most important opportunistic infection after kidney transplant, with increased in mortality, morbidity and higher costs of transplantation.
- Trial name
- StopCMV (NCT02671318)
- Testing
- Drug conversion to sirolimus, Maintenance of the current regimen
- Where
- Brazil
- Volunteers
- 250 people
- Sponsor
- Hospital do Rim e Hipertensão
Transplant Rejection, Renal Transplantation
Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients
Sirolimus, 1 mg, white, triangular tablets (Rapamune®) was approved on 03 April 2007 in China for prophylaxis of organ rejection in renal transplantation.
- Trial name
- NCT01236378
- Testing
- Sirolimus
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Pfizer
Kidney Transplant; Complications
Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants
The primary purpose of this study is to evaluate the pulse wave velocity and vascular compliance measurements at the beginning and the end of the study while the participants are taking either extended release tacrolimus tablets…
- Trial name
- PTAAK (NCT03841097)
- Testing
- Extended Release Tacrolimus Tablets, Immediate Release Tacrolimus Capsule
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Roy D. Bloom, MD
Difference of 12-hour AUC
Pharmacokinetic of Everolimus and Atorvastatin Co-administration
Hypothesis : In renal transplantation recipient who received immunosuppressive drug "certican" and have hypercholesterolemia will get lipid lower drug-HMG Co-A reductase inhibitors.
- Trial name
- NCT01780948
- Testing
- Atorvastatin 20 mg, Everolimus
- Where
- Thailand
- Volunteers
- 18 people
- Sponsor
- Chulalongkorn University
Acute Renal Failure
Low Dose Thymoglobin in Renal Transplant Patients
This is a planned single center prospective randomized study evaluating the safety and efficacy of low dose thymoglobulin as induction agent in renal transplant recipients.
- Trial name
- NCT01280617
- Testing
- Thymoglobulin, Thymoglobulin 0.75mg/kg dose
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Lahey Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.